Amarin Corp. PLC (NASDAQ:AMRN) fell 3.4% during trading on Monday . The company traded as low as $2.57 and last traded at $2.58, with a volume of 1,766,419 shares traded. The stock had previously closed at $2.67.

A number of brokerages have recently commented on AMRN. Jefferies Group reaffirmed a “buy” rating and set a $3.50 price objective on shares of Amarin Corp. PLC in a research note on Thursday, July 7th. Zacks Investment Research raised shares of Amarin Corp. PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, July 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Amarin Corp. PLC in a research note on Monday, August 8th.

The company’s market cap is $489.06 million. The stock’s 50 day moving average price is $3.04 and its 200-day moving average price is $2.19.

Amarin Corp. PLC (NASDAQ:AMRN) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.06. The firm earned $32.82 million during the quarter, compared to analysts’ expectations of $29.97 million. During the same quarter in the prior year, the firm posted ($0.15) EPS. Amarin Corp. PLC’s quarterly revenue was up 85.4% compared to the same quarter last year. Equities analysts expect that Amarin Corp. PLC will post ($0.46) earnings per share for the current fiscal year.

Large investors have recently modified their holdings of the stock. KCG Holdings Inc. boosted its stake in shares of Amarin Corp. PLC by 1.2% in the second quarter. KCG Holdings Inc. now owns 73,026 shares of the biopharmaceutical company’s stock worth $158,000 after buying an additional 900 shares in the last quarter. State Street Corp boosted its stake in shares of Amarin Corp. PLC by 2.4% in the second quarter. State Street Corp now owns 104,259 shares of the biopharmaceutical company’s stock worth $225,000 after buying an additional 2,491 shares in the last quarter. ProShare Advisors LLC boosted its stake in shares of Amarin Corp. PLC by 0.9% in the second quarter. ProShare Advisors LLC now owns 132,338 shares of the biopharmaceutical company’s stock worth $286,000 after buying an additional 1,180 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in shares of Amarin Corp. PLC by 9.3% in the second quarter. Ameriprise Financial Inc. now owns 1,187,983 shares of the biopharmaceutical company’s stock worth $2,567,000 after buying an additional 101,112 shares in the last quarter. Finally, Timber Hill LLC boosted its stake in shares of Amarin Corp. PLC by 229.8% in the second quarter. Timber Hill LLC now owns 53,504 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 37,283 shares in the last quarter. Institutional investors own 20.74% of the company’s stock.

Amarin Corp. PLC Company Profile

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

5 Day Chart for NASDAQ:AMRN

Receive News & Ratings for Amarin Corp. PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corp. PLC and related companies with MarketBeat.com's FREE daily email newsletter.